Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Daiichi Sankyo Ltd ADR (DSNKY)

Daiichi Sankyo Ltd ADR (DSNKY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 40,576,996
  • Shares Outstanding, K 1,894,351
  • Annual Sales, $ 12,449 M
  • Annual Income, $ 1,952 M
  • EBIT $ 667 M
  • EBITDA $ 1,120 M
  • 60-Month Beta N/A
  • Price/Sales 3.27
  • Price/Cash Flow 17.01
  • Price/Book 3.71
  • Price/Earnings ttm 20.14
  • Earnings Per Share ttm 1.06
  • Most Recent Earnings $0.32 on 07/31/25
  • Next Earnings Date 01/01/70
  • Annual Dividend & Yield 0.32 (1.51%)
  • Most Recent Dividend 0.179 on 09/27/25
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/25
See More
  • Average Estimate 0.34
  • Number of Estimates 1
  • High Estimate 0.34
  • Low Estimate 0.34
  • Prior Year 0.22
  • Growth Rate Est. (year over year) +54.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.5100 +4.44%
on 12/22/25
24.7700 -13.52%
on 11/26/25
-2.3000 (-9.70%)
since 11/24/25
3-Month
20.5100 +4.44%
on 12/22/25
27.5000 -22.11%
on 10/22/25
-1.5200 (-6.63%)
since 09/24/25
52-Week
20.5100 +4.44%
on 12/22/25
29.6800 -27.83%
on 01/30/25
-6.5000 (-23.28%)
since 12/24/24

Most Recent Stories

More News
1 Biopharma Stock Setting the New Standard in Cancer Care Drugs

The annual conference of the American Society of Clinical Oncology is always the biggest event-making cancer conference. And this year, the attention-grabber was AstraZeneca, as its lung and breast cancer...

AZN : 92.45 (+0.34%)
MS : 181.65 (+1.20%)
DSNKY : 21.4200 (+0.33%)
PFE : 25.03 (+0.60%)
Forget Weight-Loss Drugs, Here's the Next Breakthrough Pharma Stock

There is another segment of the pharma industry that is as hot as weight-loss drugs: antibody-drug conjugates, or ADCs. These treatments will, in the near future, replace conventional chemotherapy, thanks...

AZN : 92.45 (+0.34%)
GMAB : 33.72 (+0.21%)
NVO : 52.56 (+1.84%)
JNJ : 207.78 (+0.97%)
MRK : 106.45 (+1.34%)
DSNKY : 21.4200 (+0.33%)
LLY : 1,076.98 (+0.50%)
ABBV : 229.89 (+0.48%)
RHHBY : 52.5300 (-0.10%)
PFE : 25.03 (+0.60%)
300,000 New Cases: The Role of Biotech in Addressing Rising Breast Cancer Rates

USA News Group – Breast cancer rates are increasing this year, with nearly 300,000 new cases of invasive breast cancer diagnosed in women and 2,800 new cases in men. While breast cancer survival rates...

ONCY : 0.9700 (+1.68%)
AZN : 92.45 (+0.34%)
ARAY : 0.8597 (+0.43%)
DSNKY : 21.4200 (+0.33%)
GILD : 125.67 (+0.38%)
ONC.TO : 1.42 (+2.16%)
Investing in Hope: Biotech Innovations Targeting Increased Breast Cancer Rates in 2023

USA News Group – Breast cancer rates are increasing this year, with nearly 300,000 new cases of invasive breast cancer diagnosed in women and 2,800 new cases in men. While breast cancer survival rates...

ONCY : 0.9700 (+1.68%)
AZN : 92.45 (+0.34%)
ARAY : 0.8597 (+0.43%)
DSNKY : 21.4200 (+0.33%)
GILD : 125.67 (+0.38%)
ONC.TO : 1.42 (+2.16%)
Merck Just Made a Big Move -- but Will It Be Enough for Investors Right Now?

In due time, its new partnership with Daiichi Sankyo could be massive.

MRK : 106.45 (+1.34%)
DSNKY : 21.4200 (+0.33%)
Is Gilead Sciences a Good Stock to Buy Now?

Gilead Sciences' breast cancer drug, Trodelvy, just took a big step forward.

AZN : 92.45 (+0.34%)
DSNKY : 21.4200 (+0.33%)
GILD : 125.67 (+0.38%)
PFE : 25.03 (+0.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Daiichi Sankyo Company Limited manufactures and sells pharmaceutical products principally in Japan, North America, Europe and internationally. Daiichi Sankyo Company Limited is based in Tokyo, Japan.

See More

Key Turning Points

3rd Resistance Point 22.5833
2nd Resistance Point 22.0267
1st Resistance Point 21.7233
Last Price 21.4200
1st Support Level 20.8633
2nd Support Level 20.3067
3rd Support Level 20.0033

See More

52-Week High 29.6800
Fibonacci 61.8% 26.1771
Fibonacci 50% 25.0950
Fibonacci 38.2% 24.0129
Last Price 21.4200
52-Week Low 20.5100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar